OncoTargets and Therapy
Volume 10, 2017 - Issue
Open access
112
Views
24
CrossRef citations to date
0
Altmetric
Original Research
Niclosamide inhibition of STAT3 synergizes with erlotinib in human colon cancer
Lingyi Shi1 Chemical Biology Research Center, School of Pharmaceutical Sciences
, Hailun Zheng1 Chemical Biology Research Center, School of Pharmaceutical Sciences
, Wanle Hu2 Department of Coloproctology, The Second Affiliated Hospital and Yuying Children’s Hospital
, Bin Zhou2 Department of Coloproctology, The Second Affiliated Hospital and Yuying Children’s Hospital
, Xuanxuan Dai3 Department of Oncological Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, People’s Republic of China
, Yi Zhang3 Department of Oncological Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, People’s Republic of China
, Zhiguo Liu1 Chemical Biology Research Center, School of Pharmaceutical Sciences
, Xiaoping Wu1 Chemical Biology Research Center, School of Pharmaceutical SciencesCorrespondence[email protected] [email protected]
, Chengguang Zhao1 Chemical Biology Research Center, School of Pharmaceutical SciencesCorrespondence[email protected] [email protected]
& Guang Liang1 Chemical Biology Research Center, School of Pharmaceutical Sciences
show all
Pages 1767-1776
|
Published online: 23 Mar 2017
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.